Using 2006–2010 Medicare data for RA patients, Yun et al. reported that among those patients who experienced a hospitalized infection while taking anti-TNFα therapy, etanercept and abatacept were associated with the lowest risk of subsequent infection compared to infliximab users [39]. Here, TNF is linked to infection.